A New Intrinsic Hypoxia Marker in Esophageal Cancer
During the past three decades, the incidence of esophageal adenocarcinoma (EAC) in the US increased by 5- to 6-fold, with a yearly increase of 4–10%.1 The prognosis for EAC is extremely poor, and the 5 year survival rate is ~10%.1−3 Despite significant improvements in early diagnosis and treatment, the majority of deaths in EAC patients are attributable to metastases that are resistant to therapy.2,3
KeywordsEsophageal Cancer Esophageal Carcinoma Esophageal Adenocarcinoma Tumor Hypoxia Esophageal Tumor
Unable to display preview. Download preview PDF.
- 4.J. Denekamp, Inadequate vasculature in solid tumours: consequences for cancer research strategies, BJR Suppl. 24, 111–7 (1992).Google Scholar
- 11.P. Okunieff, I. Ding, P. Vaupel, and M. Höckel, Evidence for and against hypoxia as the primary cause of tumor aggressiveness, Adv. Exp. Med. (in press), (2002).Google Scholar
- 18.B. M. Fenton, S. F. Paoni, B. K. Beauchamp, B. Tran, L. Liang, B. Grimwood, and I. Ding, Evaluation of microreginal variations in tumor hypoxia following the administration of endostatin, Adv. Exp. Med. (in press) (2002).Google Scholar
- 19.L. Zhang, S. Kharbanda, D. Chen, J. Bullocks, D. L. Miller, I. Y. Ding, J. Hanfelt, S. W. McLeskey, and F. G. Kern, MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice, Oncogene. 15, 2093–108 (1997).PubMedCrossRefGoogle Scholar